TY  - GEN
AU  - Fader,Amanda N
AU  - Roque,Dana M
AU  - Siegel,Eric
AU  - Buza,Natalia
AU  - Hui,Pei
AU  - Abdelghany,Osama
AU  - Chambers,Setsuko K
AU  - Secord,Angeles Alvarez
AU  - Havrilesky,Laura
AU  - O'Malley,David M
AU  - Backes,Floor
AU  - Nevadunsky,Nicole
AU  - Edraki,Babak
AU  - Pikaart,Dirk
AU  - Lowery,William
AU  - ElSahwi,Karim S
AU  - Celano,Paul
AU  - Bellone,Stefania
AU  - Azodi,Masoud
AU  - Litkouhi,Babak
AU  - Ratner,Elena
AU  - Silasi,Dan-Arin
AU  - Schwartz,Peter E
AU  - Santin,Alessandro D
TI  - Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu
SN  - 1527-7755
PY  - 2019///1003
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Carboplatin
KW  - administration & dosage
KW  - Cystadenocarcinoma, Serous
KW  - drug therapy
KW  - Female
KW  - Humans
KW  - Middle Aged
KW  - Neoplasm Staging
KW  - Paclitaxel
KW  - Progression-Free Survival
KW  - Receptor, ErbB-2
KW  - biosynthesis
KW  - Trastuzumab
KW  - Uterine Neoplasms
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
UR  - https://doi.org/10.1200/JCO.2017.76.5966
ER  -